1. Latest News
  2. Submit Press Release

"Chronic Lymphocytic Leukemia Therapeutics Market (2010 - 2020) in G8 Countries" Published

New Pharmaceuticals research report from Markets and Markets is now available from Fast Market Research

 
Feb. 14, 2012 - PRLog -- Chronic lymphocytic leukemia is the second most common cancer in adult males and rarely occurs in children. The risk of chronic lymphocytic leukemia is closely associated with age. About 90% of chronic lymphocytic leukemia is diagnosed in middle age. Incidence rate of CLL is high in men and women over 50 years of age. The chronic lymphocytic leukemia market is segmented into two types; namely childhood chronic lymphocytic leukemia and adulthood lymphocytic leukemia. The market was dominated by Campath drug in 2010. However, in 2020, the market is expected to be equally dominated by GA101/RG7159 molecule and Arzerra drug.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/290205_chronic_lymphocytic_leukemia_therapeutics_market.aspx
------------------------------------------------------------

This report studies the market from 2010 to 2020 covering seven major regimens and single drugs (off-patent and pipeline) for chronic lymphocytic leukemia treatment. At present, there are two regimens in the market; namely FC regimen and FCR regimen. Plus, there are four drugs in the market; such as Fludara (Fludarabine), Campath, Treanda, and Arzerra. Growing chronic lymphocytic leukemia population is an impetus for the growth of the market. This market is expected to grow at a CAGR of 13.43% from 2015 to 2020. North America was the major contributor to this market; accounting for 61.21% of the total sales of chronic lymphocytic leukemia drugs in 2010; whereas Campath was the major drug accounting for 42.32% of the total sales of chronic lymphocytic leukemia drugs in 2010. Fludara is highly effective in the treatment of CLL that captured the high market share of CLL market. Chronic lymphocytic leukemia is still an arena with high unmet need for early diagnosis and limited treatment options in this area.

The report studies six existing regimens and single drugs for chronic lymphocytic leukemia market. Currently, there is one major drug in pipeline for chronic lymphocytic leukemia; which is expecting a market launch by 2014; GA101/RG7159 will be launched in the market in 2014 by Genentech Inc (U.S.). The drug is expected to be priced at $409,586 for patients who take them annually.

Players are implementing various growth strategies in the market to gain a competitive edge. New product launches, product pipelines, agreements and collaborations, clinical trials, and acquisitions were the major strategies adopted by the players from January 2008 to September 2011.

Agreements and collaborations form the basic growth strategy in the chronic lymphocytic leukemia therapeutics market; accounting for 29% share in this market between January 2008 and September 2011, followed by NDA & BLA applications with a 25% share in the market and approvals with a 21% share.

Genzyme Corporation, Roche, GlaxoSmithKline Pharmaceuticals Limited, and Cephalon Inc rule the present market for chronic lymphocytic leukemia drugs; whereas Roche/Biogen Idec is expected to capture major share of the market by 2020.

Scope of the report

This chronic lymphocytic leukemia therapeutics market research report evaluates the leukemia therapeutics market with respect to the current and pipeline drugs and regimens. The report analyzes geography; forecasting revenue, and trends in each of the following submarkets:

Chemotherapy regimens
FC regimen
FCR regimen
Chemotherapy drugs
Fludara
Campath/MabCampath
Treanda
Arzerra
Pipeline drugs
GA101 / RG7159

The geographies covered under the report are

North America
U.S.
Canada
Europe
U.K.
Germany
Italy
France
Spain
Japan

Each section provides market data, market drivers, trends and opportunities, key players, and competitive outlook. This report also provides market tables for covering the sub-segments and micro-markets. Additionally, it makes ways for company profiles that cover all the sub-segments. The report has been made by keeping past trends, current happenings, and future forecasts in consideration.

Partial Table of Contents:

TABLE OF CONTENTS

1 INTRODUCTION
1.1 KEY TAKE-AWAYS
1.2 REPORT DESCRIPTION
1.3 MARKETS COVERED
1.4 STAKEHOLDERS
1.5 RESEARCH METHODOLOGY
1.5.1 MARKET SIZE
1.5.2 KEY DATA POINTS FROM SECONDARY SOURCES
1.5.3 ASSUMPTIONS MADE FOR THIS REPORT

2 EXECUTIVE SUMMARY
2.1 OVERVIEW OF THE MARKET

3 MARKET OVERVIEW
3.1 DEFINING LEUKEMIA
3.2 DEFINING CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
3.2.1 TYPES OF CHRONIC LYMPHOCYTIC LEUKEMIA
3.2.1.1 B-cell CLL
3.2.1.1.1 Hairy cell leukemia
3.2.1.2 T-cell CLL
3.2.1.2.1 Large granular lymphocytic leukemia
3.2.1.3 NK cell CLL
3.3 STAGES/PHASES OF CHRONIC LYMPHOCYTIC LEUKEMIA
3.3.1 STAGE 0
3.3.2 STAGE I
3.3.3 STAGE II
3.3.4 STAGE III
3.3.5 STAGE IV
3.3.6 RAI STAGING SYSTEM (STAGE 0, I, II, III & IV)
3.3.7 RISK FACTORS
3.3.8 DIAGNOSIS
3.3.8.1 Biopsy and bone marrow aspiration
3.3.8.2 Complete blood count (CBC) and differential
3.3.8.3 Philadelphia chromosome's presence
3.3.8.4 Spinal tap (lumbar puncture) and cerebrospinal fluid (CSF) analysis
3.3.8.5 Immunophenotyping or phenotyping by flow cytometry
3.3.9 CHRONIC LMYPHOCYTIC LEUKEMIA PREVALENCE
3.3.10 INCIDENCE & MORTALITY
3.4 MARKET STRUCTURE
3.4.1 KEY THERAPIES
3.4.1.1 Chemotherapy
3.4.1.2 Stem cell/bone marrow transplant
3.4.1.3 Radiation therapy

4 CHRONIC LYMPHOCYTIC LEUKEMIA MARKET DYNAMICS
4.1 MARKET OVERVIEW
4.2 BURNING ISSUES
4.3 WINNING IMPERATIVE
4.3.1 ROCHE STRATEGY FOCUSING ON ADDRESS UNMET MEDICAL NEEDS
4.4 MARKET DYNAMICS
4.4.1 DRIVERS
4.4.1.1 Innovative therapies to drive the market for leukemia
4.4.1.2 Oncology is the largest therapeutic market with high unmet needs
4.4.1.3 Off-label prescribing drives market growth
4.4.2 RESTRAINT
4.4.2.1 Low production capability for efficient drugs
4.4.3 OPPORTUNITIES
4.4.3.1 Limited players in the market
4.4.3.2 Growing older male population
4.4.3.3 High unmet needs offer potential for market growth

5 CHRONIC LYMPHOCYTIC LEUKEMIA PRODUCT MARKET
5.1 MARKET OVERVIEW
5.1.1 CAMPATH/MABCAMPATH
5.1.2 TREANDA
5.1.3 ARZERRA
5.1.4 FLUDARA
5.1.5 FCR REGIMEN
5.1.6 FC REGIMEN

6 CHRONIC LYMPHOCYTIC LEUKEMIA PIPELINE DRUG (PHASE III)
6.1 PIPELINE DRUG
6.1.1 GA101/RG7159

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=2902...

About MarketsandMarkets

MarketsandMarkets (M&M) is a global market research and consulting company based in the U.S. The company publishes high-level strategically analyzed reports for over ten industry verticals and serves as a business intelligence partner to Fortune 500 companies across the world.  View more research from Markets and Markets at http://www.fastmr.com/catalog/publishers.aspx?pubid=1014

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

--- End ---

Click to Share

Contact Email:
***@fastmr.com Email Verified
Source:Fast Market Research, Inc.
Phone:1.800.844.8156
Zip:01267
Location:Massachusetts - United States
Industry:Medical, Research, Biotech
Tags:Leukemia, Chronic, Lymphocytic, Drug, Pipeline, Drugsregimens, Therapeutic, Regimen, Cll, Expenses
Shortcut:prlog.org/11798766
Verified Account Email Address
Verified Account Phone Number

Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



Like PRLog?
9K2K1K
Click to Share